Full-Time
Senior Legal Counsel Data & AI Laws
Posted on 2/21/2026
Evotec
1,001-5,000 employees
Global drug-discovery services via partnerships
No salary listed
Hamburg, Germany
In Person
 Legal & Compliance (2) |
|---|
| , |
- Fully qualified lawyer with a strong passion for data protection, Artificial Intelligence and emerging technologies.
- Several years of professional experience, ideally in the Pharma or Biotech sector, including expertise in GDPR and other data and IT laws.
- Fluency in written and spoken English and German.
- Excellent communication skills with the ability to collaborate effectively across functions, cultures, and geographies
- Strong analytical and conceptual thinking, with the ability to work across disciplines and understand complex systems, and think in an interdisciplinary, networked way.
- Able to manage high workloads and legal complexity under pressure while meeting deadlines
- Proactive and solution-driven mindset with a drive for continuous learning and innovation
- Provide legal advice and lead or support the implementation of global compliance with Data and AI-related laws across Evotec SE and its affiliated companies
- Conduct or support compliance risk assessments and oversee the development of preventive and corrective measures
- Develop and maintain policies, procedures, and contract templates related to data and AI compliance
- Integrate compliance frameworks into core business functions (Operations, HR, IT, Procurement, and more)
- Monitor procurement and purchasing strategies to ensure alignment with legal and regulatory requirements
- Design and deliver internal training programs to promote awareness and understanding of data and AI laws
- Support commercial and operational teams with legal guidance for new business opportunities and advice on data and AI-related matters, including contract drafting and negotiation
- Contribute to interdisciplinary compliance initiatives and projects beyond traditional legal scope
- Support the Legal Compliance Team in driving efficiency improvements through legal tech and collaborative knowledge sharing
- Certified Information Privacy Professional (CIPP/E) or similar qualifications are a plus
Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hamburg, Germany
Founded
1993
Simplify's Take
What believers are saying
- Just-Evotec Biologics revenue surged 104% in Q4 2025 with $650M Sandoz deal.
- Horizon plan delivers €75M savings by 2027 via site optimization to 10 hubs.
- New leaders like CFO Hinshelwood and CCO Khan drive commercial execution and partnerships.
What critics are saying
- Horizon's 800 job cuts erode iPSC expertise, prompting Bristol Myers Squibb to switch providers.
- Charles River Laboratories captures discovery clients amid Evotec's restructuring disruptions.
- Schrödinger steals AI deals through faster in-silico cycles exploiting Evotec's negative EBITDA.
What makes Evotec unique
- Proprietary platforms like PanOmics and iPSC-based modeling enable precision drug discovery.
- Just-Evotec Biologics redefines affordable biologics manufacturing for partners.
- AI-driven innovation integrates with wet-lab infrastructure across small molecules and cell therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Unlimited Paid Time Off
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.
Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.
Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.
Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.
Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.